Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

FDA
News

Biogen Receives FDA Approval For Aduhelm

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178

byBenzinga Newsdesk

February 9, 2023

1 minute read

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178

Truist Securities Upgrades DCP Midstream to Buy, Announces $37 Price Target

By Benzinga Newsdesk

Today, 2:26 AM

Truist Securities analyst Tristan Richardson upgrades DCP Midstream (NYSE:DCP) from Hold to Buy and announces $37 price target.

DCP

AGNC Investment Q2 EPS $(0.97) Down From $1.33 YoY

By Benzinga Newsdesk

Today, 2:26 AM

AGNC Investment (NASDAQ:AGNC) reported quarterly losses of $(0.97) per share. This is a 172.93 percent decrease over earnings of $1.33 per share from the same period last year.

AGNC

BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

By Benzinga Newsdesk

Today, 2:26 AM

BTIG analyst Marie Thibault maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $11 to $5.

PEAR

Becton Q1 Adj EPS $2.98 Beats $2.68 Estimate, Sales $4.58B Beat $4.52B Estimate

By Benzinga Newsdesk

Today, 2:26 AM

Becton (NYSE:BDX) reported quarterly earnings of $2.98 per share which beat the analyst consensus estimate of $2.68 by 11.19 percent. The company reported quarterly sales of $4.58 billion which beat the analyst

BDX

Biogen Receives FDA Approval For Aduhelm

Related Posts

Truist Securities Upgrades DCP Midstream to Buy, Announces $37 Price Target

AGNC Investment Q2 EPS $(0.97) Down From $1.33 YoY

BTIG Maintains Buy on Pear Therapeutics, Lowers Price Target to $5

Becton Q1 Adj EPS $2.98 Beats $2.68 Estimate, Sales $4.58B Beat $4.52B Estimate